<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2963">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455181</url>
  </required_header>
  <id_info>
    <org_study_id>PAR-C10-009</org_study_id>
    <nct_id>NCT01455181</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary</brief_title>
  <acronym>REPEAT</acronym>
  <official_title>A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>Hungary: Scientific and Medical Research Council Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effect of 6-months of treatment with NPSP558 in
      reducing requirements for supplemental oral calcium and active vitamin D, while maintaining
      stable total serum calcium levels in adult subjects with hypoparathyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects either must have previously completed NPSP558 Study CL1-11-040 (REPLACE) including
      24 weeks of active therapy and 4 weeks of follow-up to Week 28 prior to enrolling in this
      study or have enrolled in REPLACE and dropped out during optimization, but currently meet
      inclusion/exclusion criteria for REPLACE.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24, Based on Investigator Prescribed Data.</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A ≥ 50% reduction from baseline in dose of oral calcium or an oral calcium dose of ≤ 500 mg and a ≥ 50% reduction from baseline in dose of oral active vitamin D (calcitriol dose of ≤ 0.25 μg/day or alphacalcidol dose of ≤ 0.50 μg/day) and a total serum calcium concentration that was normalized or maintained compared to the baseline value and did not exceed the ULN of the central laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Changes From Baseline in Active Vitamin D Dosages at Each Visit</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Changes From Baseline in Oral Calcium at Each Visit</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving the Primary Endpoint at Each Visit</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A ≥ 50% reduction from baseline in dose of oral calcium or an oral calcium dose of ≤ 500 mg and a ≥ 50% reduction from baseline in dose of oral active vitamin D (calcitriol dose of ≤ 0.25 μg/day or alphacalcidol dose of ≤ 0.50 μg/day) and a total serum calcium concentration that was normalized or maintained compared to the baseline value and did not exceed the ULN of the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in 24-hour Urine Calcium Excretion</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>NPSP558</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPSP558</intervention_name>
    <description>50, 75, 100 μg</description>
    <arm_group_label>NPSP558</arm_group_label>
    <other_name>REPEAT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet all the following inclusion criteria can be enrolled into this study:

          1. Signed and dated informed consent form (ICF) before any study-related procedures are
             performed

          2. Previously completed 24 weeks of therapy and 4 weeks of follow-up in the REPLACE
             study, OR Enrolled in REPLACE and dropped out during optimization, but currently meet
             inclusion/exclusion criteria for REPLACE

          3. Able to perform daily SC self-injections of study medication (or have a designee
             perform injection) via a multidose injection pen into the thigh

          4. Willingness and ability to understand and comply with the protocol

          5. Women who are: (1) postmenopausal defined as 12 months amenorrhea with appropriate
             serum follicle stimulating hormone (FSH) levels (&gt; 40 IU/L); (2) surgically
             sterilized; OR (3) of childbearing potential with a negative pregnancy test at
             screening and who consent to use two acceptable methods of contraception for the
             duration of the study, with pregnancy testing at every scheduled visit during the
             treatment period . Female partners (who are of childbearing potential) of male study
             patients must also use acceptable forms of contraception during their partner's
             participation

        Exclusion Criteria:

        Patients who meet any of the following exclusion criteria at baseline (Visit 1) are not
        eligible for enrollment in this study:

          1. Any condition that, in the investigator's opinion after consultation with the
             sponsor, would preclude the safe use of NPSP558

          2. Any disease or condition in the opinion of the investigator that has a high
             probability of precluding the patient from completing the study or where the patient
             cannot or will not appropriately comply with study requirements

          3. Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hjalmar Lagast, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>NPS Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Semmelweis University Medical School</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pécs, School of Medicine</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>November 10, 2015</lastchanged_date>
  <firstreceived_date>September 15, 2011</firstreceived_date>
  <firstreceived_results_date>February 20, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoparathyroidism</keyword>
  <keyword>NPSP558</keyword>
  <keyword>Parathyroid Hormone 1-84</keyword>
  <keyword>PTH 1-84</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>24 Subjects were enrolled between 8/2011 to 5/2012 at 3 Clinical sites in Hungary.</recruitment_details>
      <pre_assignment_details>Subjects previously completed 24 weeks of therapy and 4 weeks of follow-up in the REPLACE study, or enrolled in REPLACE and dropped out during optimization, but currently met inclusion/exclusion criteria for REPLACE.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NPSP558</title>
          <description>NPSP558: Recombinant Human Parathyroid hormone (rhPTH[1-84]) 50, 75, or 100 mcg subcutaneously daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NPSP558</title>
          <description>NPSP558: Recombinant Human Parathyroid hormone (rhPTH[1-84]) 50, 75, or 100 mcg subcutaneously daily.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt; 45 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>45 to 64 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>≥ 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hungary</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24, Based on Investigator Prescribed Data.</title>
        <description>A ≥ 50% reduction from baseline in dose of oral calcium or an oral calcium dose of ≤ 500 mg and a ≥ 50% reduction from baseline in dose of oral active vitamin D (calcitriol dose of ≤ 0.25 μg/day or alphacalcidol dose of ≤ 0.50 μg/day) and a total serum calcium concentration that was normalized or maintained compared to the baseline value and did not exceed the ULN of the central laboratory.</description>
        <time_frame>24 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NPSP558</title>
            <description>NPSP558: Recombinant Human Parathyroid hormone (rhPTH[1-84]) 50, 75, or 100 mcg subcutaneously daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24, Based on Investigator Prescribed Data.</title>
            <description>A ≥ 50% reduction from baseline in dose of oral calcium or an oral calcium dose of ≤ 500 mg and a ≥ 50% reduction from baseline in dose of oral active vitamin D (calcitriol dose of ≤ 0.25 μg/day or alphacalcidol dose of ≤ 0.50 μg/day) and a total serum calcium concentration that was normalized or maintained compared to the baseline value and did not exceed the ULN of the central laboratory.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75.0" lower_limit="53.3" upper_limit="90.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Changes From Baseline in Active Vitamin D Dosages at Each Visit</title>
        <time_frame>24 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NPSP558</title>
            <description>NPSP558: Recombinant Human Parathyroid hormone (rhPTH[1-84]) 50, 75, or 100 mcg subcutaneously daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Percentage Changes From Baseline in Active Vitamin D Dosages at Each Visit</title>
            <units>percentage of change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-47.08" spread="31.566"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-80.38" spread="16.688"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-96.70" spread="7.865"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-96.18" spread="11.521"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-97.92" spread="10.206"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Changes From Baseline in Oral Calcium at Each Visit</title>
        <time_frame>24 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent-to-treat population, which includes all subjects who received at least one dose of study drug and had at least one efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP558</title>
            <description>NPSP558: Recombinant Human Parathyroid hormone (rhPTH[1-84]) 50, 75, or 100 mcg subcutaneously daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Percentage Changes From Baseline in Oral Calcium at Each Visit</title>
            <units>percentage of change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.3" spread="36.20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-46.4" spread="35.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-71.5" spread="33.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-71.7" spread="38.60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-76.0" spread="40.48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving the Primary Endpoint at Each Visit</title>
        <description>A ≥ 50% reduction from baseline in dose of oral calcium or an oral calcium dose of ≤ 500 mg and a ≥ 50% reduction from baseline in dose of oral active vitamin D (calcitriol dose of ≤ 0.25 μg/day or alphacalcidol dose of ≤ 0.50 μg/day) and a total serum calcium concentration that was normalized or maintained compared to the baseline value and did not exceed the ULN of the central laboratory.</description>
        <time_frame>24 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent-to-treat population, which includes all subjects who received at least one dose of study drug and had at least one efficacy measurement .</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP558</title>
            <description>NPSP558: Recombinant Human Parathyroid hormone (rhPTH[1-84]) 50, 75, or 100 mcg subcutaneously daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Patients Achieving the Primary Endpoint at Each Visit</title>
            <description>A ≥ 50% reduction from baseline in dose of oral calcium or an oral calcium dose of ≤ 500 mg and a ≥ 50% reduction from baseline in dose of oral active vitamin D (calcitriol dose of ≤ 0.25 μg/day or alphacalcidol dose of ≤ 0.50 μg/day) and a total serum calcium concentration that was normalized or maintained compared to the baseline value and did not exceed the ULN of the central laboratory.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Week 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in 24-hour Urine Calcium Excretion</title>
        <time_frame>24 Weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The Intent-to-treat population, which includes all subjects who received at least one dose of study drug and had at least one efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP558</title>
            <description>NPSP558: Recombinant Human Parathyroid hormone (rhPTH[1-84]) 50, 75, or 100 mcg subcutaneously daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in 24-hour Urine Calcium Excretion</title>
            <units>mg/24 hour</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-64.58" spread="188.42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-51.53" spread="183.41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NPSP558</title>
          <description>NPSP558: Recombinant Human Parathyroid hormone (rhPTH[1-84]) 50, 75, or 100 mcg subcutaneously daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tetany</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Director, Clinical Development</name_or_title>
      <organization>NPS Pharmaceuticals</organization>
      <phone>+1 908-450-5300</phone>
      <email>info@npsp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
